All Q1 FY27 results →
NH

Nephrocare Health Services Ltd

Q1 FY27Healthcare Services

Nephrocare Health Services Q1 FY27 earnings call: Revenue & Margins

Q1 FY27 earnings call: what management said on revenue, margins and capex.

Price₹694
Market cap₹7.0K Cr
P/E82.0
Updated26 Aug 2026
Read4 min read

What the Q1 FY27 call signalled

2 of 3 strong

RevenueGood growth
MarginMargins steady
CapexCapex planned

The short version

Focus on platform-level ROCE-accretive investments rather than country-level details; currently in 5 countries, aiming for 10-15 countries in 5-10 years. Nephrocare Health Services Limited maintains a medium-term growth guidance of 15% to 20% CAGR over the next 3 to 5 years.

From Nephrocare Health Services Ltd's Q1 FY27 earnings-call transcript · updated 26 Aug 2026.

Revenue & Sales Performance

Good growth
- Focus on platform-level ROCE-accretive investments rather than country-level details; currently in 5 countries, aiming for 10-15 countries in 5-10 years. - Growth driven by three levers: 1. Same center growth (increased utilization) 2. Increasing footprint in existing markets (adding new clinics) 3. Market expansion via new countries, M&A, and Public-Private Partnerships (PPP). - Target to open 40-50 clinics annually in India, 10-15 clinics annually in the Philippines, and enter a new international market every 12-18 months. - Network utilization is key; capacity addition is essential since dialysis machines have fixed treatment cycles limiting volume growth without new centers.

2 more points from Nephrocare Health Services Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Nephrocare Health Services Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

Capex planned
  • Capital expenditure for Q1 FY27 was INR44 crores towards center acquisitions and growth.
  • The company intends to open 40 to 50 clinics in India and 10 to 15 clinics in the Philippines every year.
  • Plans to enter a new international market every 12 to 18 months.
  • Focus on disciplined capital allocation ensuring investments are ROCE accretive at the platform level.
  • Current investments include expanding the network, pursuing center acquisitions in both India and international markets, and paying off term loans.

2 more points from Nephrocare Health Services Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Healthcare Services

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
Rev 1Mar 3
3
Rev 2Mar 1
4
Rev 2Mar 1
5
Rev 2Mar 2
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Nephrocare Health Services Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

Some relevant points related to future growth and investments include: - The company anticipates expanding from 5 countries to 10-15 countries over the next 5 to 10 years. - Growth is driven by three levers: same center growth, footprint expansion in existing markets, and market expansion including M&A and PPP. - Saudi Arabia market entry depends on winning a nationwide tender, which will determine the number of clinics established.

2 more points from Nephrocare Health Services Ltd's call on order book

Create a free account to keep reading this call

Nephrocare Health Services Ltd — Quarterly revenue & net profit

Revenue Net profit Net loss
Dec 2024Q3 FY25
Mar 2025Q4 FY25
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26

Q1 FY27 figures are not in this chart yet. Latest shown: Mar 2026 (Q4 FY26). The Q1 FY27 numbers from the filing are in the analysis on this page.

Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹266 Cr, net profit ₹30 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

What Nephrocare Health Services's management said in earlier quarters

Others in Healthcare Services this season

  • Aatmaj Health (Q1 FY27)

    Revenue for Q1 FY 2026-27: ₹8.13 crore . Key investor presentation takeaways from Aatmaj Healthcare Ltd's Q1 FY27 investor presentation — and how it ranks again

  • Asarfi Hospital Ltd (Q1 FY27)

    Q1'FY27 consolidated revenue from operations: ₹47.5 Cr, up 32.8% YoY (vs ₹35.7 Cr in Q1'FY26) . Key investor presentation takeaways from Asarfi Hospital Ltd's Q

  • KMC Speciality (Q1 FY27)

    Q1 FY'27 Revenue from operations: INR 91.8 Cr, up 38% YoY from INR 66.6 Cr in Q1 FY'26. Key concall takeaways from KMC Speciality Hospitals (India) Ltd's Q1…

  • 3B Blackbio (Q1 FY27)

    Q1 2026-27 revenue from operations: ₹3,205.73 Lakh (including Coris sales of ₹862.83 Lakh) vs ₹1,996.06 Lakh in Q1 2025-26 — YoY growth approx. Key concall…

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Nephrocare Health Services Ltd and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Nephrocare Health Services Ltd Q1 FY27 results?

Focus on platform-level ROCE-accretive investments rather than country-level details; currently in 5 countries, aiming for 10-15 countries in 5-10 years. Nephrocare Health Services Limited maintains a medium-term growth guidance of 15% to 20% CAGR over the next 3 to 5 years.

What is Nephrocare Health Services Ltd share price analysis?

Nephrocare Health Services Ltd currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of 82.0 with a market cap of ₹6,980 Cr. Investors should review the full earnings analysis for detailed insights.

Is Nephrocare Health Services Ltd planning capital expenditure?

Capital expenditure for Q1 FY27 was INR44 crores towards center acquisitions and growth.

Keep Nephrocare Health Services Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.